Actinium Pharmaceuticals, Inc.
ATNMNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ATNM. That does not mean none is planned.
Get an email about ATNM's next catalysts
Track Actinium Pharmaceuticals (ATNM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Iomab-B
Acute Myeloid Leukemia
Cytarabine (Phase 1 only)
AML
CAR-T cell
Non Hodgkin Lymphoma
Furosemide (Phase 1 only)
AML
Lintuzumab-Ac225
AML
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Iomab-B | Phase 3 | Acute Myeloid Leukemia | - | - |
Cytarabine (Phase 1 only) | Phase 2 | AML | - | - |
CAR-T cell | Phase 2 | Non Hodgkin Lymphoma | - | - |
Furosemide (Phase 1 only) | Phase 2 | AML | - | - |
Lintuzumab-Ac225 | Phase 2 | AML | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Actinium Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 5 drug candidates in Actinium Pharmaceuticals, Inc.'s (ATNM) pipeline across Phase 3, Phase 2. Its lead program is Iomab-B (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Actinium Pharmaceuticals, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Actinium Pharmaceuticals, Inc. (ATNM) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track ATNM biotech catalysts?β
Add ATNM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Actinium Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
